Technology | Stents Bare Metal | December 09, 2015

Medinol Begins U.S. Commercialization of New Coronary Stent

NIRxcell CoCr Stent System first product launched from new U.S. headquarters

December 9, 2015 — Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the NIRxcell CoCr Stent System.

During the recent 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco, Medinol Ltd. hosted a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", where a physician panel discussed the key attributes of the NIRxcell System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved). Physician faculty included David E. Kandzari, M.D., Piedmont Heart Institute; Jim Zidar, M.D., North Carolina Heart and Vascular; Rajiv Jauhar, M.D., North Shore University Medical Center; Peter Smits, M.D., Maasstad Ziekenhuis, Rotterdam, the Netherlands; and Shmuel Banai, M.D., The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Discussion highlighted key product features and emphasized the design of the BIONICS/NIREUS clinical trials that have recently completed enrollment. 

Kandzari commented, "The delivery system is unlike in any other product on the market" and Medinol's approach to trial design "was entirely unlike any other pivotal trial as it included a 'more comers' patient population."

On an annual basis, approximately 800,000 patients undergo coronary stenting procedures in the United States. Healthcare providers continue to look for novel, effective and efficient solutions to treat their patients.

For more information: www.medinol.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major